Novel Bacillus Probiotic Strains

About Sporegen

Sporegen is a pioneering private biotech firm specializing exclusively in Bacillus spore technology, positioning itself as a unique player in the global market. Its platform centers on developing heat-stable mucosal vaccines (SporeVax®), targeted drug delivery for oncology, and novel probiotic strains, aiming to address significant unmet needs in vaccine stability and targeted therapy. The company appears to be in a pre-clinical or early development stage, engaging in contract services to support its R&D while building a proprietary pipeline. Its strategic sponsorship of international conferences indicates an active effort to establish scientific credibility and partnerships within the field.

Therapeutic Areas